English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 7 November 2017, 09:53 HKT/SGT
Share:
    

Source: Hitachi, Ltd.
Hitachi Announces Pharmacotherapy Outcome Prediction Technology for Drug Selection Support in Type-2 Diabetes Mellitus
Data-driven approach to support pharmacotherapy selection

TOKYO, Nov 7, 2017 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) today announced the development of a machine learning-based outcome prediction and comparison technology that predicts with high accuracy the success and failure of various medication options for patients with type-2 diabetes mellitus (T2DM), in collaboration with University of Utah Health (U of U Healt). The technology analyzes electronic medical records and creates a prediction model which calculates the probability of different medications attaining a target value for hemoglobin A1c (HbA1c)(1) after 90 days of commencing treatment, thus potentially helping medical practitioners choose the most effective medication option. The high accuracy(2) of the technology in predicting the effectiveness of various medications was confirmed using simulation on past records of patients with diabetes.

Currently, the importance of value-based healthcare, which aims to realize both better outcomes while reducing healthcare costs, is receiving attention worldwide. In the United States, the number of patients with diabetes has risen to about 23 million, and one in four people over the age of 65 is diagnosed with T2DM(3). Treatment of T2DM spans from several months to several years or more, during which time the drug(s) selected and the dosage(s) need to be adjusted based on the patient's condition. This significant variability in pharmacotherapy regimens often leads to a trial-and-error approach in drug selection.

Hitachi has been working on developing various measures to address diabetes using IT, such as life-style modification support and diabetes prevention services(4). In this research collaboration, the knowledge and experience of Hitachi, and doctors, pharmacists and biomedical informaticists at the U of U Health, were used to develop technology to predict the probability of achieving a treatment target with each medication. In developing the technology, data from approximately 6,800 patients were analyzed chronologically from various aspects such as drug category, dosage, treatment period, weight, trend in test results, etc. Machine learning techniques were then applied to the resulting information to build a prediction model for HbA1c, generating patient-specific predictions of the effectiveness of alternate treatment options. Using the resulting model, it is possible to predict and compare the effectiveness of treatment at 90-days, a common period in the United States between clinic visits for patients whose diabetes therapy is being adjusted. As a result, the technology has the potential to support the selection of the most effective medication depending on the patient's background and condition. The technology was verified using data from another 2,200 patient files by simulation, and the highly accurate nature of the predictions was confirmed.

Hitachi will continue this collaborative research with U of U Health to realize the practical application of this technology and its development of healthcare informatics technologies that support medical practitioners and patients with improved healthcare outcomes(5). Additionally, part of these results will be presented at the IEEE-NIH Special Topic Conference on Healthcare Innovation and Point-of-Care Technologies to be held from 6th to 8th November 2017, in Bethesda, Maryland, U.S.A.

(1) HbA1c:Laboratory test value which reflects average blood sugar level for the past two to three months.
(2) AUC (Area Under the Curve) of 0.85. The area under the Receiver Operator Curve (ROC) represents prediction model performance with a value range from 0.5 to1 (ideal).
(3) Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017
(4) For more information on Hitachi's services, please reference: Proof of Concept Project for a Diabetes Prevention Service in Greater Manchester, United Kingdom. A Hitachi Review, 64 (No. 1):
(5) Implementation of this technology will require due diligence to ensure sufficient protection of personal information and privacy.

About University of Utah Health

University of Utah Health is the state's only academic health care system, providing leading-edge and compassionate medicine for a referral area that encompasses 10% of the U.S. A hub for health sciences research and education in the region, U of U Health has a $291 million research enterprise and trains the majority of Utah's health care professionals at its Schools of Medicine and Dentistry and Colleges of Nursing, Pharmacy and Health. Staffed by more than 20,000 employees, the system includes 12 community clinics and four hospitals. For eight straight years, U of U Health has ranked among the top 10 U.S. academic medical centers in the Vizient Quality and Accountability Study, including reaching No. 1 in 2010 and 2016.

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is focusing on Social Innovation Business that combines information technology (IT), operational technology (OT) and products. The company's consolidated revenues for fiscal 2019 (ended March 31, 2020) totaled 8,767.2 billion yen ($80.4 billion), and the number of employees was approximately 301,000 worldwide. Hitachi delivers digital solutions utilizing Lumada in five sectors including Mobility, Smart Life, Industry, Energy and IT, to increase social, environmental and economic values of its customers. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.

Contact:
Hitachi Ltd
Corporate Communications
Tel: +81-3-3258-1111


Source: Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501)

Topic: Press release summary
Sectors: Cloud & Enterprise, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
Hitachi, Ltd. Links

http://www.hitachi.com

https://www.facebook.com/hitachi.global/

https://twitter.com/hitachiglobal?lang=en

https://www.youtube.com/user/HitachiBrandChannel

https://ph.linkedin.com/company/hitachi

Hitachi, Ltd. Releated News
Oct 19, 2020 11:00 HKT/SGT
日立、数十人、数百人規模の最適な勤務シフトを作成するソリューションを提供開始
Oct 15, 2020 16:41 HKT/SGT
Hitachi Acquired Additional Shares to Hold Majority of Shares of Yungtay, Elevator Company Based in Taiwan
Oct 15, 2020 09:00 HKT/SGT
日立ABBパワーグリッド社がUKパワー・ネットワークスサービス社から英国の高速列車専用線HS1の電気設備更新工事を受注
Oct 14, 2020 16:48 HKT/SGT
Hitachi ABB Power Grids Wins $6.6 Million Projects to Digitalize High-Speed Rail in the UK
Oct 13, 2020 15:25 HKT/SGT
Hitachi ABB Power Grids and Tensio TN AS to deliver Norway's First Fully Digital, Eco-efficient Substation
More news >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575